BACKGROUND: The effect of activation of endogenous transforming growth factor-beta (TGF-beta) on smooth muscle cell apoptosis was assessed in human saphenous vein. METHODS: Segments of human saphenous vein, obtained at the time of bypass graft surgery, were cultured for 14 days. During this time, smooth muscle cells accumulated in the intima as a result of proliferation and migration, partly counterbalanced by apoptotic cell death. RESULTS: Addition of exogenous TGF-beta(1) had no effect on smooth muscle cell proliferation or apoptosis. However, antibody neutralization of endogenous TGF-beta(1) caused significant increases in smooth muscle cell death in the media and intima without any change in proliferation. A plasmin inhibitor (alpha-N-acetyl-L-lysine methyl ester), a specific urokinase-type plasminogen activator (uPA) inhibitor (amiloride) and an anti-catalytic anti-uPA antibody all caused decreases in the tissue content of active TGF-beta and increases in smooth muscle cell death in the media and intima. CONCLUSIONS: These data suggest that the amount of TGF-beta in human saphenous vein is sufficient, when in the active form, to protect smooth muscle cells against apoptosis. Adding exogenous TGF-beta(1) has no beneficial effect, but decreasing the amount of active TGF-beta causes smooth muscle cells to undergo apoptosis. Plasmin, generated by uPA, appears to be an important activator of endogenous latent TGF-beta. Copyright (c) 2005 S. Karger AG, Basel.
BACKGROUND: The effect of activation of endogenous transforming growth factor-beta (TGF-beta) on smooth muscle cell apoptosis was assessed in human saphenous vein. METHODS: Segments of human saphenous vein, obtained at the time of bypass graft surgery, were cultured for 14 days. During this time, smooth muscle cells accumulated in the intima as a result of proliferation and migration, partly counterbalanced by apoptotic cell death. RESULTS: Addition of exogenous TGF-beta(1) had no effect on smooth muscle cell proliferation or apoptosis. However, antibody neutralization of endogenous TGF-beta(1) caused significant increases in smooth muscle cell death in the media and intima without any change in proliferation. A plasmin inhibitor (alpha-N-acetyl-L-lysine methyl ester), a specific urokinase-type plasminogen activator (uPA) inhibitor (amiloride) and an anti-catalytic anti-uPA antibody all caused decreases in the tissue content of active TGF-beta and increases in smooth muscle cell death in the media and intima. CONCLUSIONS: These data suggest that the amount of TGF-beta in human saphenous vein is sufficient, when in the active form, to protect smooth muscle cells against apoptosis. Adding exogenous TGF-beta(1) has no beneficial effect, but decreasing the amount of active TGF-beta causes smooth muscle cells to undergo apoptosis. Plasmin, generated by uPA, appears to be an important activator of endogenous latent TGF-beta. Copyright (c) 2005 S. Karger AG, Basel.
Authors: Shinsuke Kikuchi; Lihua Chen; Kevin Xiong; Yukihiro Saito; Nobuyoshi Azuma; Gale Tang; Michael Sobel; Thomas N Wight; Richard D Kenagy Journal: J Vasc Surg Date: 2017-06-21 Impact factor: 4.268
Authors: Helen Williams; Jason L Johnson; Christopher L Jackson; Stephen J White; Sarah J George Journal: Cardiovasc Res Date: 2010-02-05 Impact factor: 10.787
Authors: Zamaneh Kassiri; Gavin Y Oudit; Vijay Kandalam; Ahmed Awad; Xiuhua Wang; Xiuhua Ziou; Nobuyo Maeda; Andrew M Herzenberg; James W Scholey Journal: J Am Soc Nephrol Date: 2009-04-30 Impact factor: 10.121
Authors: Jeffrey C Horowitz; David S Rogers; Richard H Simon; Thomas H Sisson; Victor J Thannickal Journal: Am J Respir Cell Mol Biol Date: 2007-07-26 Impact factor: 6.914
Authors: L J A C Hawinkels; H W Verspaget; W van Duijn; J M van der Zon; K Zuidwijk; F J G M Kubben; J H Verheijen; D W Hommes; C B H W Lamers; C F M Sier Journal: Br J Cancer Date: 2007-07-17 Impact factor: 7.640